Myriad Making Good Deals

Some drug deals are better than others. Yesterday, Rule Breakers pick Myriad Genetics (Nasdaq: MYGN  ) announced a particularly strong partnership deal for its lead drug, Flurizan.

Flurizan is currently in late-stage testing as a treatment for Alzheimer's disease. The marketing agreement that Myriad inked with European pharma H. Lundbeck A/S will bring $100 million in cash immediately, with the potential for another $250 million in milestone payments. 

It also includes a tiered escalating royalty rate of 20% to 39% on all of Lundbeck's sales of Flurizan, less the amount paid for the bulk drug, if it gets approved for marketing. In exchange, Myriad cedes Lundbeck its marketing rights to the drug throughout Europe.

The Lundbeck deal is definitely a bit of a hedge on Myriad's part, as some analysts noted. Myriad is only a month away from announcing study results for the first of two pivotal phase 3 studies for Flurizan, with a second phase 3 study expected to produce data "around the end of 2008." Had Myriad waited until after these study results were announced (assuming they were positive), it would have greatly strengthened its partnership bargaining power.

Then again, Myriad's idea to get at least $100 million for a drug that many analysts think has a fairly high likelihood of failing in testing is not a bad one. Investors following the neurology drug treatment space right now are understandably worried about experiencing deja vu. This time last year, another high-risk Alzheimer's-disease drug developer, BELLUS Health (Nasdaq: BLUS  ) -- then known as Neurochem -- issued a large dilutive financing ahead of its pivotal phase 3 Alzheimer's drug data, to hedge against negative study results.

Other details make this deal a good one for Myriad. The company didn't give up anything close to all the potential fruits of its Flurizan labors; it will retain U.S. rights to the drug, which it also wants to partly partner out. In addition, Myriad still stands to gain a very healthy royalty rate on Lundbeck's European sales of a compound that will be expensive to promote. 

Just as importantly, Lundbeck has some good experience in marketing Alzheimer's-disease drugs because it has the European rights to the Alzheimer's drug that Forest Laboratories (Nasdaq: FRX  ) markets as Namenda in the U.S.

The deal may have its downsides, but on the whole it looks like a smart move for Myriad.

Myriad is an active pick of our Rule Breakers newsletter. You can check out all our other recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has an A+ disclosure policy.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 651833, ~/Articles/ArticleHandler.aspx, 10/23/2014 12:45:19 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement